

SLR 10/27/05 6235-59216-01 444981 MED-A0101P-US

PATENT

IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Morishita et al.

Application No. 09/857,719

Filed: December 3, 2001

Confirmation No. 9622

For: GENE THERAPY FOR CARDIOMYOPATHY

Examiner: Q. Janice Li

Art Unit: 1632

Attorney Reference No. 6235-59216-01

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP ISSUE FEE, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent  
for Applicant(s)

Date Mailed October 27, 2005

MAIL STOP ISSUE FEE  
COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. §1.97

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. This Information Disclosure Statement ("IDS") is being filed after payment of the issue fee. Applicants understand that the PTO will place these documents in the application file.

This statement is provided in compliance with 37 C.F.R. § 1.97(e)(1). The undersigned hereby certifies that each item of information contained in the IDS filed herewith was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the IDS.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,


KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 595-5300  
Facsimile: (503) 595-5301

By

Sheree Lynn Rybak, Ph.D.  
Registration No. 47,913

cc: Docketing

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

Attorney Docket Number	6235-59216-01
Application Number	09/857,719
Filing Date	December 3, 2001
First Named Inventor	Morishita
Art Unit	1632
Examiner Name	Q. Janice Li

**U.S. PATENT DOCUMENTS**

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee

**FOREIGN PATENT DOCUMENTS**

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		Europe	EP 0 847 757 A1	17.06.1998	Sumitomo Pharmaceuticals Company, Limited

**OTHER DOCUMENTS**

Examiner's Initials*	Cite No. (optional)	
		Accession No. PREV200000243247 (March, 2000).
		Accession No. NLM11425038 (2000).
		Aoki et al., "Angiogenesis Induced by Hepatocyte Growth Factor in Non-Infarcted Myocardium and Infarcted Myocardium: Up-Regulation of Essential Transcription Factor for Angiogenesis, etc.," <i>Gene Therapy</i> 7:417-427 (2000).
		Tomita et al., "Novel Molecular Therapeutic Approach to Cardiovascular Disease Based on Hepatocyte Growth Factor," <i>J. Atheroscler. Thromb.</i> 7:1-7 (2000).
		Ueda et al., "Gene Transfection of Hepatocyte Growth Factor Attenuates Reperfusion Injury in the Heart," <i>Ann. Thorac. Surg.</i> 67:1726-1731 (1999).

EXAMINER  
SIGNATURE:DATE  
CONSIDERED:

\* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.